These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 26324996)
21. Randomized Controlled Trial to Determine the Efficacy of Early Switch From Vancomycin to Vancomycin Alternatives as a Strategy to Prevent Nephrotoxicity in Patients With Multiple Risk Factors for Adverse Renal Outcomes (STOP-NT). Carreno JJ; Kenney RM; Divine G; Vazquez JA; Davis SL Ann Pharmacother; 2017 Mar; 51(3):185-193. PubMed ID: 27838680 [TBL] [Abstract][Full Text] [Related]
22. Vancomycin and nephrotoxicity: just another myth? Davies SW; Guidry CA; Petroze RT; Hranjec T; Sawyer RG J Trauma Acute Care Surg; 2013 Nov; 75(5):830-5. PubMed ID: 24158202 [TBL] [Abstract][Full Text] [Related]
23. Daily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients. Lin H; Yeh DD; Levine AR Crit Care; 2016 Jul; 20(1):205. PubMed ID: 27363312 [TBL] [Abstract][Full Text] [Related]
24. Retrospective review of vancomycin-induced nephrotoxicity in patients with leukemia. Fullmer A; McCue D; Feng C J Oncol Pharm Pract; 2014 Dec; 20(6):403-8. PubMed ID: 24177356 [TBL] [Abstract][Full Text] [Related]
25. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Gomes DM; Smotherman C; Birch A; Dupree L; Della Vecchia BJ; Kraemer DF; Jankowski CA Pharmacotherapy; 2014 Jul; 34(7):662-9. PubMed ID: 24753221 [TBL] [Abstract][Full Text] [Related]
26. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Gauthier TP; Wolowich WR; Reddy A; Cano E; Abbo L; Smith LB Antimicrob Agents Chemother; 2012 May; 56(5):2392-6. PubMed ID: 22371891 [TBL] [Abstract][Full Text] [Related]
27. High Single-dose Vancomycin Loading Is Not Associated With Increased Nephrotoxicity in Emergency Department Sepsis Patients. Rosini JM; Davis JJ; Muenzer J; Levine BJ; Papas MA; Comer D; Arnold R Acad Emerg Med; 2016 Jun; 23(6):744-6. PubMed ID: 26850378 [TBL] [Abstract][Full Text] [Related]
29. Continuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients. Hong LT; Goolsby TA; Sherman DS; Mueller SW; Reynolds P; Cava L; Neumann R; Kiser TH J Crit Care; 2015 Oct; 30(5):1153.e1-6. PubMed ID: 26239323 [TBL] [Abstract][Full Text] [Related]
30. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Lodise TP; Lomaestro B; Graves J; Drusano GL Antimicrob Agents Chemother; 2008 Apr; 52(4):1330-6. PubMed ID: 18227177 [TBL] [Abstract][Full Text] [Related]
31. Risk factors for acute kidney injury in adult patients receiving vancomycin. Cappelletty D; Jablonski A; Jung R Clin Drug Investig; 2014 Mar; 34(3):189-93. PubMed ID: 24385282 [TBL] [Abstract][Full Text] [Related]
32. Incidence and predictors of vancomycin-associated nephrotoxicity. Moh'd H; Kheir F; Kong L; Du P; Farag H; Mohamad A; Zurlo JJ South Med J; 2014 Jun; 107(6):383-8. PubMed ID: 24945176 [TBL] [Abstract][Full Text] [Related]
33. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066 [TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Hermsen ED; Hanson M; Sankaranarayanan J; Stoner JA; Florescu MC; Rupp ME Expert Opin Drug Saf; 2010 Jan; 9(1):9-14. PubMed ID: 20021290 [TBL] [Abstract][Full Text] [Related]
35. Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous versus intermittent infusion. Hanrahan T; Whitehouse T; Lipman J; Roberts JA Int J Antimicrob Agents; 2015 Sep; 46(3):249-53. PubMed ID: 26141230 [TBL] [Abstract][Full Text] [Related]
36. Impact of a Pharmacist-Initiated Vancomycin Monitoring Program. Smith AP; Millares-Sipin CA; James M; Cohen H Consult Pharm; 2016 Sep; 31(9):505-10. PubMed ID: 27636875 [TBL] [Abstract][Full Text] [Related]
37. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Pritchard L; Baker C; Leggett J; Sehdev P; Brown A; Bayley KB Am J Med; 2010 Dec; 123(12):1143-9. PubMed ID: 21183005 [TBL] [Abstract][Full Text] [Related]
38. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Meaney CJ; Hynicka LM; Tsoukleris MG Pharmacotherapy; 2014 Jul; 34(7):653-61. PubMed ID: 24700598 [TBL] [Abstract][Full Text] [Related]
39. Reducing acute kidney injury due to vancomycin in trauma patients. Ko A; Harada MY; Barmparas G; Jay J; Sun BJ; Chen E; Mehrzadi D; Patel B; Mason R; Ley EJ J Trauma Acute Care Surg; 2016 Aug; 81(2):352-7. PubMed ID: 27192471 [TBL] [Abstract][Full Text] [Related]
40. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Elting LS; Rubenstein EB; Kurtin D; Rolston KV; Fangtang J; Martin CG; Raad II; Whimbey EE; Manzullo E; Bodey GP Cancer; 1998 Dec; 83(12):2597-607. PubMed ID: 9874468 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]